Definice úspěchu v léčbě HS, biologická selekce a tlak na komorbiditu: rozhovor s Dr. Jennifer Hsiao

Dermatologists now have three approved biologics for the treatment of moderate-to-severe hidradenitis suppurativa (HS); bimekizumab joined adalimumab and secukinumab in November 2024 as the first dual IL-17A and IL-17F inhibitor for the disease.³ All three are injectable agents that target tumor necrosis factor-α or IL-17 signaling; oral Janus kinase (JAK) inhibition is the closest mechanism to them.

HCPLive: How do you decide which of the approved biologics to start with and when to switch? Jennifer Hsiao, MD: “We are really fortunate to have three FDA-approved therapies. We have adalimumab, a TNF-α inhibitor; secukinumab, an IL-17A inhibitor; and bimekizumab, an IL-17A/IL-17F inhibitor. At this point, adalimumab and secukinumab are approved for patients 12 years and older, which helps with our treatment choices in terms of age range. At this stage, I really think about the patient’s preferences. A patient may come in and say, ‘I heard this about this drug. I definitely don’t want to start on it.’ It’s also important to take into account what the patients have heard; because if you have options and someone is strongly against one for a particular reason, you may not want to push it on that visit. The patient’s comorbidities also play a role, and ultimately, access plays a role.

HCPLive: If a patient is willing to try a medication, I really want to get that medication into their hands as quickly as possible. With delays, patients may say, “You know, there’s more than enough difficulty in this,” and you may miss a window of time when they’re open to starting therapy. Insurance formulas often come into play here, and I think strong bridges and patient assistance programs can be helpful. But ultimately, our goal is to identify the patient during that window of opportunity, hopefully in early moderate disease, to start them with one of the three therapies we have available and help them start to mitigate disease progression or at least feel better at the moment.

When thinking about JAK inhibitors, the first thing I am happy about is that we will have an oral option. There are still some patients who are afraid of injections, so it would be nice to be able to offer a different route of administration. Then there are the patients I mentioned; perhaps the pathophysiology of HS is not dominated by one cytokine and is more heterogeneous. By inhibiting a pathway such as the JAK-STAT cascade, it may be beneficial for these patients to affect a greater number of cytokines. So, definitely, we need more treatments in our toolbox and it is exciting to have drugs on the horizon. I think JAK inhibitors are probably the most advanced; povorcitinib is an JAK1-selective inhibitor that recently published a paper with efficacy and safety data up to 54 weeks. It would be really exciting to have access to these drugs once they are approved.

For other comorbidities, you can hire a primary care provider who can help with many of them. On the dermatology side, I believe that one is a tobacco smoker and can recognize this; but on the first visit, it should not be brought up that you should quit smoking. It can be brought up at a later visit after you have established a relationship with the patient and clearly state that you are doing this from a general health perspective, not because you are not interested in smoking, or because you do not believe that smoking causes HS or that they are somehow at fault for HS. Doing this is really important.